Fluphenazine online

Elidel
Faslodex
Idarubicin
Entacapone

Fluphenazine

Excreted over the 36-h collection period. However, there was a biphasic profile in the biliary secretion of TRO-Sulf and TRO-Gluc in TR animals. There was a decrease in the rate of secretion of TRO-Sulf over the first 2 h and TRO-Gluc over the first 4 h collection intervals in TR rats Fig. 6 ; . These findings support the hypothesis that there is a compensatory low-affinity biliary transporter for both metabolites that participates after the metabolites accumulate in hepatocytes. In agreement with these data, an alternative biliary transport mechanism was recently proposed in Bsep knockout mice Wang et al., 2001. And reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res. 1999; 14: 256-263. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry. Indapamide, a thiazide-like diuretic, is just as likely as any other thiazide diuretic to cause hyponatraemia and hypokalaemia, especially when used in high doses. Low dose or very low dose thiazides should be used in older patients. Monitor patients on thiazide diuretics for electrolyte disturbance. If diagnosed early, stopping the drugs and encouraging fluid intake will be all that is necessary to reverse the changes. Older patients should not be too extreme with sodium restricted diets!

Quinolone-resistance-determining regions of Chlamydia trachomatis and characterisation of quinolone-resistant mutants obtained in vitro. Antimicrobial Agents and Chemotherapy 42, 247481. 10. Ridgway, G. L., Owen, J. M. & Oriel, J. D. 1976 ; . A method for testing the antibiotic susceptibility of Chlamydia trachomatis in a cell culture system. Journal of Antimicrobial Chemotherapy 2, 716. 11. Fenelon, L. E., Mumtaz, G. & Ridgway, G. L. 1990 ; . The invitro antibiotic susceptibility of Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 26, 7637. 12. Vila, J., Ruiz, J., Goni, P. & De Anta, M. T. J. 1996 ; . Detection of mutations in quinolone-resistant clinical isolates of Escherichia coli. Antimicrobial Agents and Chemotherapy 40, 4913. 13. Bbar, C. M., Grau, O., Charron, A., Renaudin, H., Gruson, D. & Bbar, C. 2000 ; . Cloning and nucleotide sequence of the DNA gyrase gyrA ; gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin. Antimicrobial Agents and Chemotherapy 44, 271927. 14. Gibreel, A., Sjgren, E., Kaijser, B., Wretlind, B. & Skld, O. 1998 ; . Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC. Antimicrobial Agents and Chemotherapy 42, 32768. 15. Takahashi, S., Hagiwara, T., Shiga, S., Hirose, T. & Tsukamoto, T. 2000 ; . In vitro analysis of the change in resistance of Chlamydia trachomatis under exposure to a sub-MIC levofloxacin for a therapeutic term. Chemotherapy 46, 4027. 16. Roblin, P. M., Montalban, G. & Hammerschlag, M. R. 1994 ; . Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrobial Agents and Chemotherapy 38, 15889. 17. Roblin, P. M., Dumornay, W. & Hammerschlag, M. R. 1992 ; . Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. Journal of Clinical Microbiology 30, 196871. INJECTION, OPRELVEKIN, 5 MG NEUMEGA ; INJECTION, OMALIZUMAB, 5 MG Xolair ; INJECTION, ORPHENADRINE CITRATE, UP TO 60 MG INJECTION, PHENYLEPHRINE HCL, UP TO 1 ML INJECTION, CHLOROPROCAINE HYDROCHLORIDE, PER 30 ML INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG INJECTION, OXYMORPHONE HCL, UP TO 1 MG INJECTION, PALIFERMIN, 50 MCG Kepivance ; INJECTION, PAMIDRONATE DISODIUM, PER 30 MG INJECTION, PAPAVERINE HCL, UP TO 60 MG INJECTION, OXYTETRACYCLINE HCL, UP TO 50 MG INJECTION, PALONOSETRON HCL, 25 MCG Aloxi ; INJECTION, PARICALCITOL, 5 MCG INJECTION, PARICALCITOL, 1 MCG INJECTION, PEGAPTANIB SODIUM, 0.3 MG MACUGEN ; INJECTION, PEGADEMASE BOVINE, 25 IU Adagen ; INJECTION, PEGFILGRASTIM, 6 MG NEULASTA ; INJECTION, PENICILLIN G PROCAINE, AQUEOUS, UP TO 600, 000 UNITS INJECTION, PENTASTARCH, 10% SOLUTION, 100 ML Pentaspan ; INJECTION, PENTOBARBITAL SODIUM, PER 50 MG INJECTION, PENICILLIN G POTASSIUM, UP TO 600, 000 UNITS INJECTION, PIPERACILLIN SOD TAZOBACTAM SOD 1G 0.125G 1.125GM ; PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, PER 300 MG, ADMINISTERED THROUGH INJECTION, PROMETHAZINE HCL, UP TO 50 MG INJECTION, PHENOBARBITAL SODIUM, UP TO 120 MG INJECTION, OXYTOCIN, UP TO 10 UNITS INJECTION, DESMOPRESSIN ACETATE, PER 1 MCG INJECTION, PREDNISOLONE ACETATE, UP TO 1 ML INJECTION, TOLAZOLINE HCL, UP TO 25 MG INJECTION, PROGESTERONE, PER 50MG PROGESTERONE OIL ; INJECTION, FLUPHENAZINE DECANOATE, UP TO 25 MG INJECTION, PROCAINAMIDE HCL, UP TO 1 GM INJECTION, OXACILLIN SODIUM, UP TO 250 MG INJECTION, NEOSTIGMINE METHYLSULFATE, UP TO 0.5 MG INJECTION, PROTAMINE SULFATE, PER 10 MG INJECTION, PROTIRELIN, PER 250 MCG INJECTION, PRALIDOXIME CHLORIDE, UP TO 1 GM INJECTION, PHENTOLAMINE MESYLATE, UP TO 5 MG INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG INJECTION, QUINUPRISTIN DALFOPRISTIN, 500MG 150 350 ; INJECTION, RANITIDINE HCL, 25 MG INJECTION, RASBURICASE, 0.5 MG ELITEK ; INJECTION, RHO D IMMUNE GLOBULIN, HUMAN MINIDOSE, 50 MCG MICRhoGAM ; INJECTION, RHO D IMMUNE GLOBULIN, HUMAN, ONE DOSE PACKAGE INJECTION, RHO D IMMUNE GLOBULIN, INTRAVENOUS, HUMAN, SOLVENT DETERGENT, 100 IU WinRho SD ; INJECTION, RISPERIDONE, LONG ACTING, 0.5 MG Risperdal Consta ; INJECTION, ROPIVACAINE HCL, 1MG INJECTION, METHOCARBAMOL, UP TO 10 ML INJECTION, SINCALIDE, 5 MCG Kinevac ; INJECTION, THEOPHYLLINE, PER 40 MG INJECTION, SARGRAMOSTIM GM-CSF ; , 50 MCG LEUKINE ; INJECTION, SECRETIN, SYNTHETIC, HUMAN, 1 MCG SecreFlo ; INJECTION, AUROTHIOGLUCOSE, UP TO 50 MG INJECTION, SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE INJECTION, 12.5 MG INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE, UP TO 40 MG INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE, UP TO 125 MG INJECTION, SOMATREM, 1 MG INJECTION, SOMATROPIN, 1 MG INJECTION, PROMAZINE HCL, UP TO 25 MG INJECTION, RETEPLASE, 18.1MG INJECTION, STREPTOKINASE, PER 250, 000 IU INJECTION, ALTEPLASE RECOMBINANT, PER 1 MG INJECTION, STREPTOMYCIN, UP TO 1 GM INJECTION, FENTANYL CITRATE, 0.1MG.
Author Contributions: Study concept and design: Al-Khatib, Allen LaPointe, Kramer, Califf. Acquisition of data: Al-Khatib, Allen LaPointe. Analysis and interpretation of data: Al-Khatib, Allen LaPointe, Kramer. Drafting of the manuscript and obtaining funding: Al-Khatib, Califf. Critical revision of the manuscript for important intellectual content: Allen LaPointe, Kramer, Califf. Administrative, technical, or material support: Al-Khatib, Allen LaPointe, Califf. Study supervision: Kramer. Funding Support: This study was supported in part by grant U18HS10548 from the Agency for Healthcare Research and Quality, Rockville, Md. Acknowledgment: The following persons participated in a survey and convened in August 2000 to discuss the current knowledge of LQTS. Academic participants: Mark E. Anderson, John T. Bigger, Jr, Robert M. Califf, Robert R. Fenichel, David A. Flockhart, Augustus O. Grant, Ralph Lazzara, Kerry L. Lee, Marek Malik, Joel Morganroth, Arthur J. Moss, Milton Packer, Ileana L. Pina, Eric N. Prystowsky, Dan M. Roden, Jeremy N. Ruskin, Michael Sanguinetti, Gordon F. To and flurazepam. HECA452 ; antibody, or of 4-integrin were negligible after over-night cytokineincubation data not shown ; . We next sought to study whether the functional changes noted in our in vitro studies were of consequence for BM homing. WT-to-WT transplantation of overnight SCF-incubated BM-HPC was first tested, after 3 h and after 18 h. Overall BM homing of overnight SCF-incubated cells was not statistically different from that of fresh cells Fig. 2B + C ; Overnight incubation with SCF + PTX reduced BM homing by 75% Fig. 2D ; compared to similarly incubated WT BM-HPC without PTX, in keeping with our earlier data.21 Overnight SCF-incubated BMHPC were also short-term treated with or without AMD3100, as described above for fresh BM cells, and BM homing was quantified after 3 h. Similarly to PTX, AMD3100 significantly reduced BM homing of cytokine-incubated cells Fig. 2B ; . To address potential effects of different length of PTX-incubation 4 h for fresh, overnight for SCF-incubated BM-HPC in additional experiments, BM-HPC were incubated with SCF overnight, and PTX was added for the last four hours of the incubation. PTX-treatment of SCF-incubated BM-HPC for the final 4 hours of the incubation reduced BM homing by almost 75% data not shown ; , similarly to cells treated with PTX throughout, alleviating these concerns. To test whether the observed dependence on Gi protein signals for BM homing of SCF-incubated BM-HPC was specific to SCF, or rather a more general characteristic of cytokine-incubation, BM-HPC were incubated with TPO instead of SCF, in the presence or absence of PTX. Just like SCF-incubation, over-night TPO + PTX-incubation led to 75% reduced BM homing compared to incubation with TPO alone Fig. 3A ; . The cooperation of Gi-protein signals with 4-integrin remained.

Cost of Fluphenazine

In addition to addressing the complex issues dis cussed above, the agency has had to consider advances in the scientific data that are the basis of the health claim and rapid changes in the regulatory environment in which the agency acts. The relevant scientific ad and flurbiprofen. LCMP-00214-2006. R1 ; 4 gene expression in IPAH PASMC would be predicted to increase the number of functional SOC and ROC, enhance vasoconstrictor- and mitogen-mediated increases in [Ca2 + ]cyt, stimulate vasoconstriction and promote cell growth. The second messenger cAMP activates cAMP-dependent protein kinase A PKA ; and or directly binds to target proteins, thereby regulating cell contraction, proliferation, apoptosis, and gene expression 36 ; . Binding of cAMP to the regulatory R ; -subunits of PKA facilitates dissociation of its catalytic C ; -subunits, thereby promoting phosphorylation of substrates that include the cAMP-response element-binding CREB ; protein. Phosphorylated CREB recruits the CREB-binding protein CBP ; , a transcriptional co-activator, and stimulates the transcription of genes that contain the CREB-binding sequences, CRE, in their promoter region 25, 52 ; . Increased cytosolic cAMP can also affect membrane channel functions by PKA-independent pathways 11, 50 ; . A rise in cellular cAMP or activated PKA can promote pulmonary vasodilation 1, 17 ; and exert antiproliferative and pro-apoptotic effects 35, 50 however, the precise mechanisms are unclear. In this study, we sought to study whether: a ; TRPC channels are regulated by cAMP differently in PASMC from normal subjects, NPH patients and IPAH patients, and b ; short- and longer-term treatment with cAMP-elevating compounds differentially affects TRPC channel activity and expression in normal, NPH and IPAH PASMC. Extractions with 1 ml hexane alone. Extraction efficiency was determined by the addition of tracer amounts of [`4C]cholesterol and [3H]cholesteryl oleate New England Nuclear, Boston, MA ; to each tube before extraction The extraction efficiency for cholesterol was 97.0 f 2.0% and for cholesteryl esters was 99.2 + 0.7%. The pooled extracts were dried under Nz, dissolved in hexane, divided into two equal aliquots free cholesterol and total cholesterol ; , and dried. One set of samples total cholesterol ; was saponified at 80 C for 1 h in 1.78 N KOH in 90% ethanol. The samples were diluted with an equal volume of water, the lipids were extracted three times with 1 ml hexane, and the pooled extracts were dried under NZ. All of the samples free cholesterol and total cholesterol ; were treated with cholesterol oxidase to convert the cholesterol to cholestenone. The cholestenone was quantitated by HPLC Waters Associates, Inc, Milford, MA ; utilizing a PBondaPak C-18 column and an acetonitrile-isopropanol gradient with detection at 254 nm 29 ; . The data represent the mean + SEM of the number of determinations and were analyzed by analysis of variance and multiple t tests to compare differences among treatment groups. Experiments were repeated at least three times and fluvastatin.

Fluphenazine Prolixin ; is available in three different salt forms, which give it varying degrees of antipsychotic potency. The decanoate and enanthate salt forms have the longest durations of action, and the hydrochloride salt form is fairly short in duration. Fluphenazine has the greatest potency of all the phenothiazines: 1 mg of the drug has the antipsychotic potency of 200 mg of chlorphenazine. It is primarily used to treat psychotic disorders and schizophrenia. It is considered a high-potency antipsychotic and is therefore associated with a high incidence of EPS; however, the associated incidence of sedative, anticholinergic, and cardiovascular effects is low. It is contraindicated in patients who have shown a hypersensitivity reaction to phenothiazines and in those suffering from circulatory collapse, liver dysfunction, blood dyscrasias, comatose state, bone marrow depression, or alcohol or barbiturate withdrawal. The two longacting salt forms, decanoate and enanthate, are available as 25-mg mL intramuscular injections. The hydrochloride salt form is available in oral form as a 2.5-mg 5 mL elixir; a 5-mg mL solution; and 1-, 2.5-, 5-, and 10-mg tablets. It is also available as a 2.5-mg mL intramuscular injection. Pregnancy category C. The commonly recommended dosages are given in the table above. PHARMACOKINETICS Half-Life PO: 15-16 hr * IM: Up to 2 Onset PO HCl ; : 1 hr HCl ; : 1 hr enanthate ; : 24-72 hr IM decanoate ; : 24-72 hr Peak PO HCl ; : 1.5-2 hr IM HCl ; : 1.5-2 hr IM enanthate ; : Unknown IM decanoate ; : Unknown Duration PO HCl ; : 6-8 hr IM HCl ; : 6-8 hr IM enanthate ; : 1-3 wk IM decanoate ; : 4 wk.

Fluphenazine side

Some nutrient transporters Pardridge, 1995 ; or up-regulation of Mrp Gutmann et al., 1999b ; ] make in vitro to in vivo extrapolation difficult. Compared with typical in vivo biodistribution studies that assess the amounts of brain-"associated" drug i.e., adsorbed to tissues, in the brain vasculature ; , in situ perfusion methods measure actual drug uptake. The in situ brain perfusion technique has been used to investigate the mechanisms of transport of various drugs across the BBB Smith, 1996 ; . We validated the in situ perfused mice brain model before performing the studies to elucidate the mechanisms of brain uptake of SQV. A perfusion rate of 2.1 ml min, at which a similar Kin value for diazepam was obtained in a previous report Dagenais et al., 2000 ; , was chosen since the physical integrity of the BBB was also maintained. [14C]Diazepam permeates the BBB by passive diffusion via the transcelluar route Takasato et al., 1984 ; , and the results of kinetic studies Fig. 1B ; confirmed and focalin. SD, Lawrence EC. Lymphocyte subset populations in bronchiolitis obliterans after heart-lung transplantation. Transplantation 1990; 50: 955959. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Eng J Med 1990; 323: 17291735. Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147: 725732. Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Acad Dermatol 1999; 40: 649671. Takahashi M, Shimatsu Y, Kazama T, Kimura K, Otsuka T, Hashimoto T. Paraneoplastic pemphigus associated with bronchiolitis obliterans. Chest 2000; 117: 603607. Hoffman MA, Qiao X, Anhalt GJ. CD8zve T lymphocytes.
The characteristics of paRace 0.56 2 0.97 tients who refused treatment White 27 66 26 Black 13 32 14 and comparison patients are Other 1 2 1 reported in table 1. This was Sex 0.53 1 0.82 a chronic group of patients, Male 27 66 26 with 91% having been hospiFemale 14 34 15 talized previously and a meAdmission legal status 1.12 1 0.29 Involuntary 35 85 38 dian of 3.4 prior hospitalizaVoluntary 6 15 3 tions. Many subjects were Insurance status 9.33 1 0.002 unemployed, which led to Insurance 20 49 7 low socioeconomic class cateNo insurance 21 51 34 Diagnosis 0.14 3 0.99 gorizations. The data on preSchizophrenia 19 46 20 vious refusals of treatment Depression 6 15 6 were collected from patients' Mania 11 27 11 hospital charts and probably Other 5 12 4 represent an underestimation Socioeconomic class 29 ; 2.83 4 0.59 actual lifetime refusal be2 8 20 7 cause all records were not 3 11 27 available for all patients; in 4 10 addition, some treatment re5 17 41 23 Prior refusal of antipsychotic medication 15.8 1 fusals may not have been reNo 30 73 12 corded. Yes 11 27 29 The rate of refusal for the Medication 2.27 7 0.94 group was 12.9%. The greatChlorpromazine 5 12 3 est number of refusals began Thioridazine 1 2 1 Trifluoperazine 2 5 the day of admission N Fluphenazine 6 15 7 six 15% ; began Perphenazine 8 20 6 the day after admission. Thiothixene 7 17 6 Forty-four percent of refusals Haloperidol 10 24 11 Mesoridazine 2 5 2 began within 72 hours of adAntiparkinsonian medication 1.27 1 0.26 mission. The mean number No 22 54 days between admission Yes 19 46 14 and treatment refusal 8.7 days, SD 12.3 ; is skewed Mean SD Mean SD t df skewness, 2.9 ; by the presence of two patients who did Age years ; 35.9 9.7 33.2 not refuse treatment until Number of previous hospitalizations 3.6 2.5 5.7 Dose of antipsychotic medication mg of more than 30 days after adchlorpromazine equivalents ; 302.1 185.6 441.5 mission 38 and 64 days, BPRS total admission score 39.7 9.4 46.9 respectively ; . Therefore, the median number of days from admission to refusal 5 days ; admission legal status, socioeconomic class 29 ; , disis a better measure of central tendency. charge diagnosis, or prescribed antipsychotic medicaMost patients 68%, N 28 ; ended their refusal within tions. Patients who refused antipsychotic medication 2 days, which was the median length of refusal; 90% N 37 ; refused treatment for no longer than 4 days. The differed from the comparison patients in several ways. mean length of refusal 2.8 days, SD 3.3 ; was skewed Patients who refused medication were more likely to skewness, 4.4 ; by one refusal episode that lasted 21 days. have a history of refusal of antipsychotic medications table 1 were significantly more likely to be uninsured Characteristics of Patients Who Refused Treatment and suffered greater psychopathology, as indicated by total BPRS scores; and were prescribed higher doses of The groups that refused and accepted treatment did antipsychotic medication in chlorpromazine equivanot differ significantly on measures of age, race, gender, lents 30 ; . Although a smaller proportion of refusers and follistim.

After obtaining the in vitro susceptibility results, and in one patient, the dose of fluconazole was increased to 800 mg day. The patient with the susceptible dose-dependent isolate first received higher doses of fluconazole and was later switched to amphotericin B. Of the four patients in whom the susceptibility of the isolate was not known, one was switched to itraconazole, one suffered from a urinary tract infection, which was successfully treated with a single dose of 400 mg fluconazole and two died as a result of other medical complications of their underlying disease within 2 and 40 days, respectively, after initiation of fluconazole treatment.

Combining gcs with other prophylactic methods lduh, lmwh, or ipc ; may give better protection; * data shows benefit of plantar pneumatic compression in orthopedic total joint arthroplasty and leg trauma and can be used when ipc not feasible or tolerated and formoterol. Arch Ophthalmol. 2002; 120: 586-594 tomas.8-10 Theoretically, macular translocation may be useful for treating atrophic macular disease by placing the fovea over healthier RPE, which could prevent the loss of photoreceptors and sustain foveal function. This article presents the results of limited macular translocation in both eyes of a patient with atrophic macular disease, presumed to be caused by pattern dystrophy, who had poor visual acuity for a prolonged period of time prior to the procedure and fluphenazine. Rhodanese and CS aggregation assays The ability of CaM and S100 proteins to inhibit rhodanese aggregation and CS aggregation was assayed essentially as described previously 28, 29 ; . CaM and S100 proteins were equilibrated for 5 min at 25Cin 95 l of Hepes, pH 7.0 and 100 mM NaCl. After adding 5 l of 37.5 M rhodanese or 35.6 M CS in guanidineHCl and 50 mM Hepes, pH 7.0, the rate of the aggregation of these proteins was determined by measuring the increase in absorbance at 320 nm. Aggregation was essentially completed after 15 min. Effects of fluphenazine and prenylamine on the chaperone activity of S100A1 were measured by the CS aggregation assay as described above and forteo. Figure 4. Dependence of alternative oxidase activity on Q redox state in mitochondria oxidizing N A D the presence of succinate and malonate. The assays were carried out in the presence of 6 p~ myxothiazol and were performed as descrihed in "Materials and and Methods." Titrations with increasing NADH in the ahsence O ; presence W ; of 5 pyruvate and titrations in the presence of 10 mM succinate and 25 mM malonate A ; . Titration of A. maculatum A, mitochondria 55 pg protein [protl mL-' ; . B, Titration of soyhean cotyledon mitochondria 250 Fg mitochondrial protein [protl mL-'. Recommended for restricted use within NHS Scotland. Restricted to patients under the overall supervision of clinicians experienced in managing this complex disorder. Recommended for general use within NHS Scotland and fortovase.

Fluphenazine mechanism of action

Fluphenazin, fluphenaazine, fluphneazine, fluphenwzine, fluphfnazine, fluphenazinee, fluphennazine, fluphenzzine, fluphenzaine, fluphenazinr, fluphenazime, fluph4nazine, fl7phenazine, fluphenazinw, fluphenazie, luphenazine, flyphenazine, cluphenazine, flupheenazine, flhphenazine, fluphenazzine, fluphenaxine, flupheanzine, fluphenaz8ne, tluphenazine, fluphehazine, fluphenazne, fluhpenazine, fluphenazune, flupjenazine, flupyenazine, fluphenszine, fluphenqzine, flupphenazine, fluphemazine, fluphenasine, fluphenazihe, fluphnazine, flupbenazine, fluphhenazine, fl8phenazine, flphenazine, flkphenazine, fljphenazine, fluphenazibe, fluphenaziine, rluphenazine, fluphenazjne.

Fluphenazine nail

Cost of fluphenazine, fluphenazine side, fluphenazine mechanism of action, fluphenazine nail and fluphenazine generic for. History of fluphenazine, fluphenazine taper, fluphenazine for equine and fluphenazine toxicity or fluphenazine vial.

VPS for GBP5.99 Only